Evaluation of the Effectiveness of the Self-developed Pulmonary Lobar Ventilation Detector
NCT ID: NCT05799040
Last Updated: 2024-03-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
40 participants
OBSERVATIONAL
2023-10-26
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will use the self-developed pulmonary lobar ventilation detector and the imported Chartis detection system to evaluate the target pulmonary lobar collateral ventilation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Warning Value of Consumer Wearable Devices in AECOPD
NCT05974670
Home-based Pulmonary Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease
NCT04722224
Continuous Versus Interval Walking Training in Patients With COPD - a Pilot Study
NCT02209207
Study on the Prevention and Control System of Chronic Airway Diseases
NCT04348344
The Use of Medical Devices to Monitor Chronic Obstructive Pulmonary Disease Patients Study BREATH-TRACHER 1
NCT06419036
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Self-developed pulmonary lobar ventilation detector
Self-developed pulmonary lobar ventilation detector
The participants would evaluated by the self-developed pulmonary lobar ventilation detector.
imported Chartis detection system
Chartis detection system
The participants would evaluated by the Chartis detection system.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Self-developed pulmonary lobar ventilation detector
The participants would evaluated by the self-developed pulmonary lobar ventilation detector.
Chartis detection system
The participants would evaluated by the Chartis detection system.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* FEV1 ≤ 45% pred and FEV1/FVC\<70%
* TLC\>100% pred and RV\>175% pred
* CAT≥18
* \>50% of emphysema destruction
* Smoking prohibition\>6 months
* Sign the informed consent form
Exclusion Criteria
* 6-minute walking test\<160m
* Obvious chronic bronchitis, bronchiectasis or other infectious lung diseases
* Three hospitalizations due to pulmonary infection in the past 12 months before the baseline assessment
* Previous lobectomy, LVRS or lung transplantation
* LVEF\<45% and or RVSP\>50mmHg
* Anticoagulant therapy that cannot be stopped before surgery
* The patient has obvious immune deficiency
* Participated in other lung drug studies within 30 days before this study
* Pulmonary nodules requiring intervention
* Any disease or condition that interferes with the completion of the initial or subsequent assessment
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
China-Japan Friendship Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gang Hou
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-NHLHCRF-LX-01-0202-3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.